Meeting
2015 Gastrointestinal Cancers Symposium
A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).
Authors
Adam Charles Yopp
The University of Texas Southwestern Medical Center, Dallas, TX
Adam Charles Yopp , Amit G Singal , Yull Edwin Arriaga , Udit N. Verma , Joseph Shan , Nikoletta Kallinteris , Muhammad Shaalan Beg , John C. Mansour , Hao Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01264705
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 345)
DOI
10.1200/jco.2015.33.3_suppl.345
Abstract #
345
Poster Bd #
C14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).
First Author: Arndt Vogel
Poster
2015 Gastrointestinal Cancers Symposium
Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
First Author: Ann-Lii Cheng
Poster
2014 Gastrointestinal Cancers Symposium
Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
First Author: Ghassan K. Abou-Alfa
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of modulation of sorafenib (SOR)-induced autophagy using hydroxychloroquine (HCQ) in advanced hepatocellular cancer (HCC): Planned interim efficacy and safety analysis.
First Author: Sukeshi Patel Arora